CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food...
More Miles, Less Fatigue: Walking Poles and CMT
Travel means more time on your feet, navigating new terrain like cobblestones, stairs, gravel, or uneven pavement....
Is Spinal Fluid the Way to Gene Therapy in CMT? What a Decade of Research Reveals
Most kinds of CMT come from a problem in a single gene. Repairing that faulty...
CMTA Leading the Way in CMT1A
CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
CMTA research takes the stage at PNS
PNS 2026 showcased CMTA's role in advancing CMT research across the translational pipeline, from biomarkers and natural history studies to clinical trials, therapeutic development, and the scientific collaborations driving progress.
What Filspari Means for People with CMTDIE
FDA approval of Filspari creates a new treatment option for FSGS that may benefit some people living with CMTDIE. Learn why this milestone matters.
CMTA Expands Preclinical Toolbox with New CMT1A Assay
CMTA expands its Preclinical Toolbox with a new CMT1A assay, providing researchers with a human-relevant platform to evaluate potential therapies earlier in drug development.
What 465 People with CMT1A Want Researchers to Know
Results from a patient survey conducted by CMTA, CMT France, and Nervosave Therapeutics highlight what matters most to people living with CMT1A.
The Biggest Battle Wasn’t CMT
Arienna Hauser-Brown reflects on growing up with Charcot-Marie-Tooth disease (CMT) and how learning to overcome self-doubt transformed the course of her life.
Fighting Forward: My Life with CMT
Mother of three shares her biohacking journey with CMT.
